Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD

BACKGROUND: Phase III studies demonstrated efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY) in subjects with COPD. Secondary analyses were performed to examine the effect of background long-acting beta(2)-agonist (LABA) use on the efficacy and safety of nebulized GLY. METHOD...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Chron Obstruct Pulmon Dis
Egile Nagusiak: Kerwin, Edward M, Tosiello, Robert, Price, Barry, Sanjar, Shahin, Goodin, Thomas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6157543/
https://ncbi.nlm.nih.gov/pubmed/30275690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S172408
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak